Hilltop Holdings Inc. Boosts Stock Position in Amgen Inc. $AMGN

Hilltop Holdings Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 715.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,524 shares of the medical research company’s stock after buying an additional 25,905 shares during the period. Hilltop Holdings Inc.’s holdings in Amgen were worth $8,332,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Evelyn Partners Investment Management LLP bought a new position in Amgen during the second quarter valued at approximately $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen in the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC bought a new stake in shares of Amgen in the 3rd quarter worth approximately $34,000. AXS Investments LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at $42,000. Finally, Winnow Wealth LLC bought a new position in shares of Amgen during the 3rd quarter valued at $47,000. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock opened at $366.21 on Monday. The company’s fifty day simple moving average is $357.73 and its two-hundred day simple moving average is $325.68. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market cap of $197.41 billion, a PE ratio of 25.74, a price-to-earnings-growth ratio of 3.63 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. Amgen’s dividend payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Rothschild & Co Redburn lifted their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. UBS Group boosted their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Jefferies Financial Group assumed coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $354.00.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.